CD274 and neoplasm: Besides approved tests like immunohistochemistry of PD-L1, tumour mutational burden (TMB) or microsatellite instability (MSI), experimental tests are gradually verified in predicting cancer therapy outcomes, namely immunoscore, TCR diversity, circulating immune-related proteins, and microbiome [25].